share_log

Oppenheimer Assumes Seres Therapeutics at Outperform, Announces Price Target of $12

Benzinga ·  Jun 26, 2023 06:47

Oppenheimer analyst Mark Breidenbach assumes Seres Therapeutics (NASDAQ:MCRB) with a Outperform rating and announces Price Target of $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment